Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.
Anti-malarial Drugs are available only with a physician's prescription. They come in tablet, capsule, and injectable forms. Among the commonly used anti-malarial drugs are chloroquine, mefloquine, primaquine, pyrimethamine, and quinine.
Market Analysis and Insights: Global Drugs for Malaria Market
Due to the COVID-19 pandemic, the global Drugs for Malaria market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type accounting for % of the Drugs for Malaria global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Type segment is altered to an % CAGR throughout this forecast period.
In the U.S. market, the major manufacturers are Cipla, Guilin Southern Medicine, IPCA Laboratories, GlaxoSmithKline, Mylan Labs, Roche, Novartis, Sanofi Aentis and Ajanta Pharma, etc, with about 73% market shares.
Global Drugs for Malaria Scope and Market Size
The global Drugs for Malaria market is segmented by company, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Drugs for Malaria market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
Segment by Type
Aryl Aminoalcohol Compounds
Antifolate Compounds
Artemisinin Compounds
Segment by Application
Prevention
Treatment
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Cipla
Guilin Pharmaceutical
IPCA Laboratories
GlaxoSmithKline
Mylan Labs
Roche
Novartis
Sanofi Aventis
Ajanta Pharma